About
OncoLattice Bio is built to bring AI-native oncology trial intelligence into real-world drug development. The company operates independently as a commercial entity while using technology and research foundations developed through the broader Apex AI ecosystem under appropriate licensing and governance structures.
Team
OncoLattice Bio is led across commercial strategy and technical development to support oncology sponsors with FIH planning, site diligence, competitor intelligence, and global development strategy. Team information is presented for company context and does not imply that any nonprofit institution provides commercial client services.
Chief Executive Officer / Head of Commercial Strategy and Partnerships
University of Waterloo alumnus responsible for company strategy, commercialization, client development, and strategic partnerships. At OncoLattice Bio, Zhipei focuses on translating site-level trial intelligence, competitor analysis, and China-to-global development needs into management-ready decision materials for oncology biotech sponsors, pharma BD teams, and strategic partners.
Chief Technology Officer / Medical AI Systems Lead
Physician-scientist and medical AI technology expert focused on AI medical systems, robotic surgery, oncology clinical applications, and real-world clinical workflows. Dr. Yuan leads technology strategy, clinical intelligence methodology, data-product architecture, and platform quality boundaries so OncoLattice Bio's intelligence layer remains interpretable, reviewable, and useful for development decisions.
Commercial engagement, contracting, and delivery are handled through OncoLattice Bio / AAI Inc. under appropriate governance.
Apex AI relationship
OncoLattice Bio is the commercial translation partner built to bring AI-native oncology trial intelligence into real-world drug development. The company operates independently as a commercial entity while leveraging technology and research foundations developed through the broader Apex AI ecosystem under appropriate licensing and governance structures.
Built on research foundations from the Apex AI ecosystem.
Supported by licensed AI infrastructure for commercial deployment through OncoLattice Bio / AAI Inc.
Structured to separate nonprofit research activities from commercial execution.
Expert governance
Dr. Jianda Yuan is publicly listed as an Advisor to Apex AI Institute. His background in translational immuno-oncology and oncology product development provides important professional context for the broader AAI ecosystem. Commercial engagements through OncoLattice Bio are separately governed and do not imply automatic individual participation.
View public AAI advisor bioThe site references public AAI advisory context as a credibility signal, not as a promise of direct personal client service.
Commercial projects are contracted and delivered through OncoLattice Bio / AAI Inc. under separate governance.
Expert input, where appropriate, is subject to authorization, conflict review, and written approval.
Named affiliations are for professional background only. No current or former employer endorses OncoLattice Bio, Apex AI Institute, or any commercial engagement. Individual advisor involvement in any commercial project requires separate authorization, conflict review, and written approval.